BioNTech SE Sponsored ADR $BNTX Shares Acquired by Victory Capital Management Inc.

Victory Capital Management Inc. increased its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 97.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 413,685 shares of the company’s stock after acquiring an additional 203,700 shares during the quarter. Victory Capital Management Inc. owned approximately 0.18% of BioNTech worth $37,531,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of BNTX. Vontobel Holding Ltd. grew its holdings in shares of BioNTech by 17.9% during the third quarter. Vontobel Holding Ltd. now owns 72,096 shares of the company’s stock valued at $7,110,000 after purchasing an additional 10,924 shares during the last quarter. Allianz SE lifted its holdings in shares of BioNTech by 635.0% in the 2nd quarter. Allianz SE now owns 5,880 shares of the company’s stock worth $626,000 after purchasing an additional 5,080 shares during the last quarter. Dodge & Cox bought a new stake in shares of BioNTech in the 2nd quarter worth approximately $93,421,000. Lingohr Asset Management GmbH increased its position in BioNTech by 598.4% in the third quarter. Lingohr Asset Management GmbH now owns 47,643 shares of the company’s stock worth $4,699,000 after buying an additional 40,821 shares during the period. Finally, LBP AM SA lifted its stake in BioNTech by 15.7% in the third quarter. LBP AM SA now owns 353,329 shares of the company’s stock valued at $34,845,000 after buying an additional 47,859 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Trading Down 0.4%

Shares of NASDAQ:BNTX opened at $101.50 on Friday. The company has a 50 day moving average of $106.82 and a 200-day moving average of $103.14. The company has a current ratio of 7.12, a quick ratio of 7.02 and a debt-to-equity ratio of 0.01. The firm has a market cap of $22.86 billion, a P/E ratio of -38.59 and a beta of 1.51. BioNTech SE Sponsored ADR has a twelve month low of $81.20 and a twelve month high of $124.00.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Jefferies Financial Group reissued a “buy” rating and set a $151.00 price target on shares of BioNTech in a report on Wednesday, December 3rd. Berenberg Bank reiterated a “buy” rating on shares of BioNTech in a research report on Friday, January 23rd. UBS Group raised shares of BioNTech to a “hold” rating in a research note on Thursday, December 4th. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and upped their target price for the stock from $115.00 to $142.00 in a research report on Friday, January 16th. Finally, HC Wainwright restated a “buy” rating and issued a $140.00 price target on shares of BioNTech in a research note on Thursday, December 11th. Eleven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $140.10.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.